Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. Our team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, IL, Exicure conducts its discovery and development efforts in-house with a dedicated 30,000 sq. ft. facility, including rapid and automated high throughput nucleic acid synthesis and screening. Our platform for therapeutic nucleic acids demonstrates high potency, broad uptake, and prolonged efficacy in both in vitro and in vivo neurological models. The basis of our discovery approach harnesses our expertise in oligonucleotide chemistry to validated targets where we can screen thousands of oligonucleotides efficiently and validate top candidates in the appropriate cell and live animal models. Exicure's lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A (Nav1.7). Exicure has also identified several promising candidates across a series of CNS conditions with high unmet need including Huntington disease, Angelman syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis.